Therapeutic Response

EGFR Exon 19 (Deletion) status confers therapeutic sensitivity to Carboplatin in combination with Osimertinib and Pemetrexed in patients with Non-Small Cell Lung Cancer.

Statements

Source and description

Tagrisso (osimertinib) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to osimertinib in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test. This indication is based on FLAURA2 (NCT04035486), a randomized, multicenter, and open-label trial where patients were randomized to receive either osimertinib or osimertinib in combination with pemetrexed and investigator's choice of either cisplatin or carboplatin.